- This is a retrospective global study looking at long term treatment regimens and effectiveness of Ranibizumab for macular degeneration. Tasmanian Eye Institute was the highest global recruiting site for this study. This follows on from a large patient series Assoc. Prof. Vote has presented at international meetings about real world insights into the benefit of treatment for our patients with macular degeneration.
2. Luminous Research
- This is a 5 year global prospective study aimed to advance the understanding of retinal vascular diseases causing vision loss. It also aims to evaluate the long-term effectiveness and safety of Ranibizumab in clinical practice across large populations, in order to further enhance patient outcomes.
- This is an Australian based multi-centre study to evaluate the effectiveness of Ranibizumab injections in patients with diabetic macular oedema (DME) (both well controlled and poorly controlled diabetes mellitus).
- A phase IV, multicenter study with 22 sites over Australia and New Zealand investigating the efficacy and safety of Ranibizumab “inject and extend” using intensive and relaxed retinal fluid retreatment regimen in patients with wet AMD.
5. Prometheus and Minerva
- This is a phase III multicenter global trial evaluating Ranibizumab injections in patients with visual impairment due to vascular endothelial growth factor driven choroidal neovasularlisation and macular oedema.
6. Effect of tropicamide on intraocular pressure
- This study is a retrospective observational study that seeks to analyse if tropicamide eye drops, routinely used in pupillary dilation/mydriasis to enable the effective examination of the posterior segment of the eye, affects intraocular pressures.
7. Femto Second Laser
- As one of the first researchers in the world into Femto Second laser technology, Assoc. Prof Vote and his team have been collecting data in the largest published prospective comparative cohort study. They have systematically been investigating potential patient benefits of Femto Second Laser pre-treatment to cataract surgery.
8. Combined Visudyne photodynamic therapy (PDT) and Lucentis study for Age Related Macular Degeneration (ARMD) Research
- This multicentre randomized controlled study investigated the impact of PDT on reducing ongoing Lucentis injection treatment for ARMD. This trial is completed and data being analysed for publication.
9. RESTORE Core & Extension Research
- This multicentre international randomised control trial explores Lucentis therapy with and without laser versus laser alone in the management of diabetic macular oedema. This study is nearing the end of two years with one further year of extension trial to complete.
10. BRVO Lucentis Research
- This multicentre randomised control trial explores Lucentis therapy with and without laser versus laser alone in the management of branch retinal vein occlusion.
11. AMD Retrospective Research
- This single site review of all patients managed with intravitreal anti VEGF agents will be the largest published series from clinical practice. Data currently being analysed.
12. AMD Genetic Research
- Improvement in genetic screening allow Genome wide screening looking for genetic associations of clinical diseases. Existing clinical phenotype data base allows screening for AMD genes.
13. Diabetic Retinopathy Genetic Research
- Improvement in genetic screening allow Genome wide screening looking for genetic associations of clinical diseases. Existing clinical phenotype data base allows screening for diabetic retinopathy genes.
14. Macular Hole genetic research
- Improvement in genetic screening allow Genome wide screening looking for genetic associations of clinical diseases. Existing clinical phenotype data base allows screening for macular hole genes.
15. TORIC intraocular lenses Research
- Single site review of all patients managed with TORIC intraocular lenses. Insights designed to improve outcomes of surgery. Data for over 500 eyes currently being analysed for publication.
16. Post-injection pain survey
- Surveys pain though infrequent is the most significant problem associated with intraocular injections. Strategies to reduce pain are currently being assessed by nursing staff.
Additional Research Support
Tasmanian Eye Institute is also participating in the national “Fight Retinal Blindness” program by being a host site for Professor David Mackey’s Tasmanian Genetics Research. Genetic Research (via blood donation) for:
- Age-related Macular Degeneration
- Diabetic retinopathy
- Macular Hole
- Retinal detachment